{"entity":{"id":"nct06961188","kind":"trial","name":"Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis","aka":[],"tldr":"A phase 3 trial in lung cancer, run by Changchun GeneScience Pharmaceutical Co., Ltd., not yet recruiting.","summary":"Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis is a phase 3, randomised interventional study registered as NCT06961188 by Changchun GeneScience Pharmaceutical Co., Ltd., with a registry enrolment figure of 174 participants, started 2025-06-01 and due to reach its primary completion in 2027-06-30. Interventions recorded: Nano-crystalline Megestrol Acetate Oral Suspension; Standard Therapy. Conditions listed: Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity; Untreated With Systemic Therapy. Primary outcome: Proportion of appetite improvement assessed by A/CS-12 (Anorexia/Cachexia Subscale of Functional Assessment of Anorexia/Cachexia Therapy); Proportion of individuals with weight gain exceeding 5% relative to baseline. Lung eligibility wording from the registry: \"* Histologically or cytologically confirmed metastatic (stage IV) driver gene-negative non-squamous non-small cell lung cancer (NSCLC) that is unresectable and not amenable to curative therapy\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06961188","url":"https://clinicaltrials.gov/study/NCT06961188"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["changchun-genescience"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06961188","phase":"3","setting":"Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in First-Line Non-Squamous Non-Small Cell Lung Cancer Patients During Pre-Cachexia and Cachexia Stages.","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","enrolled":174,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06961188/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"changchun-genescience","kind":"company","name":"Changchun GeneScience Pharmaceutical","route":"/companies/changchun-genescience/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}